GABATHER AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.815 SEK | -11.89% |
|
-17.87% | +28.72% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimerâs disease.
Calendar
30/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +28.72% | 3.64M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- GABA Stock
- News Gabather AB
- Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders